A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity

NCT07100210 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Refractory Malignant Solid Tumors
mRNA Vaccine
Interleukin

Interventions

BIOLOGICAL: IL-22BP mRNA vaccine injection

Sponsor

Xingchen Peng